Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2014. Refer to TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | nalmefene (Selincro®) | ||
| Formulation | 18 mg film-coated tablet | ||
| Reference number | 1259 | ||
| Indication | Reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification. Nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. Nalmefene should be initiated only in patients who continue to have a high DRL two weeks after initial assessment |
||
| Company | Lundbeck Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Full | ||
| Status | Superseded | ||
| Advice number | 0414 | ||
| NMG meeting date | 27/11/2013 | ||
| AWMSG meeting date | 15/01/2014 | ||
| Ratification by Welsh Government | 26/02/2014 | ||
| Date of issue | 27/02/2014 | ||
| Date of last review | 17/02/2017 | ||
| NICE guidance | TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
||